The purpose of the study is to determine if bupropion can help people reduce or stop their methamphetamine use and to investigate whether genetic variations influence whether people respond to treatment with bupropion for methamphetamine addiction, which may help doctors and patients better decide if treatment with bupropion will be beneficial or not.
Currently there are no medications approved for the treatment of methamphetamine addiction. Bupropion is an antidepressant that is approved by the Food and Drug Administration (FDA) for the treatment of depression and for cigarette smoking cessation but is not approved by the FDA for the treatment of methamphetamine addiction.
Preliminary research studies suggest that bupropion may help people receiving treatment for methamphetamine addiction to reduce or to stop their methamphetamine use. But results of these studies also suggest that bupropion may help certain groups of patients more than others, such as men versus women and light versus heavy methamphetamine users, although the reasons for this difference are not known. One possibility is that a person's genetic makeup may influence whether or not they respond to treatment with bupropion for methamphetamine addiction.
Call (866) 449-8252 if you or someone you know are interested in this outpatient study.
Read more about our bupropion study for methamphetamine addiction at ClinicalTrials.gov.
Tags:
addiction,
bupropion,
clinical trial,
crystal meth,
los angeles,
methamphetamine,
ucla
UCLA SARX is a group of world-class clinical researchers and providers in Los Angeles that specialize in clinical trials for meth addiction treatment and research along with office-based treatment for addiction to opioids, stimulants, tobacco, alcohol and marijuana. We are proudly a part of the UCLA Center for Behavioral & Addiction Medicine.
